Novartis news

Novartis on track to deliver Influenza A (H1N1) vaccine for the US

Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease

Novartis receives approval in the European Union for Exforge HCT®, a new 3-in-1 treatment for high blood pressure

Novartis delivers strong new product momentum and operational performance in first nine months of 2009

New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroid

Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec® as first-line treatment in chronic myeloid leukemia patients

Novartis receives Complete Response letter from FDA for QAB149, an investigational bronchodilator for COPD

Leading Dengue and TB scientists discuss new clinical research approaches and models of excellence for clinical research and trials in endemic regions

Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM), an FDA-approved oral therapy for schizophrenia

Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic